Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study
- 27 September 2005
- journal article
- Published by Wiley
- Vol. 60 (6) , 641-647
- https://doi.org/10.1111/j.1365-2125.2005.02502.x
Abstract
To estimate the diffusion of new safety information concerning postmenopausal hormonal replacement therapy (HRT) into prescribing practice in The Netherlands and to assess the impact of revised guidelines on the long-term treatment of HRT. Cross-sectional study. Community pharmacy dispensing data from a population of approximately 450,000 patients in the northern and eastern part of The Netherlands. Women aged 45-69 years to whom at least one HRT prescription was dispensed between 1 January 2000 and 1 January 2004. Annual and quarter prevalences of HRT and the proportion of new HRT users, switchers and continuous HRT users per quarter. The prevalence of HRT prescribing decreased significantly from 107/1000 [95% confidence interval (CI) 104, 110] in 2000 to 87/1000 (95% CI 84, 89) in 2003. The decreasing prevalence was especially evident among the younger age groups and was most pronounced among users of oestrogen/progestagen combinations. The publication of the Women Health Initiative Study (WHI) was followed by a modest decrease in prescribing of HRT, whereas prescribing of HRT declined dramatically after publication of the Million Women Study (MWS) in August 2003. Among the continuous HRT users in the 4th quarter of 2002, 55% used HRT longer than 3 years. This percentage was 53 in the 4th quarter of 2003. In contrast to the release of the WHI study results, publication of the MWS was followed by a dramatic fall in prescribing of HRT in The Netherlands. Despite the new recommendation that long-term HRT use should be discouraged, the proportion of long-term users did not change after the publication of the MWS.Keywords
This publication has 19 references indexed in Scilit:
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- National Use of Postmenopausal Hormone TherapyJAMA, 2004
- Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of usersBMJ, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation informationPharmacoepidemiology and Drug Safety, 2003
- Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal WomenJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Hormone Replacement Therapy for Secondary Prevention of Coronary Heart DiseasePublished by American Medical Association (AMA) ,1999
- HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONSAnnual Review of Public Health, 1998
- Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular DiseaseNew England Journal of Medicine, 1996